Aspire Pharma, a UK-based specialty generics pharma business, has announced the acquisition of Charlwood Pharma Ltd — a privately-owned company specialising in the research and development of niche generic medicines. The deal marks the culmination of a successful multi-year collaboration between the two organisations.

Through this acquisition, Aspire gains access to Charlwood’s strong pipeline of products across mental health, ear, nose and throat (ENT), cardiovascular and respiratory therapy areas — further strengthening its portfolio and its growth strategy.

Richard Condon, Chief Executive of Aspire Pharma, said, “This acquisition not only strengthens our existing portfolio, but also stands as a testament to the value of long-term partnerships with Aspire, which deliver meaningful innovations that enhance patient care.”

Under the terms of the agreement, Aspire will assume full ownership of all intellectual property, bolstering its ambitions for international expansion.

“This acquisition further demonstrates Aspire’s commitment to delivering quality, affordable medicines that support the highest levels of patient care, while offering true value to healthcare systems throughout the world,” Condon added.